ProShare Advisors’s Nurix Therapeutics NRIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $208K | Sell |
18,305
-1,401
| -7% | -$16K | ﹤0.01% | 1701 |
|
|
2025
Q1 | $234K | Sell |
19,706
-3,426
| -15% | -$40.7K | ﹤0.01% | 1579 |
|
|
2024
Q4 | $436K | Buy |
23,132
+7,261
| +46% | +$137K | ﹤0.01% | 1361 |
|
|
2024
Q3 | $357K | Buy |
15,871
+5,834
| +58% | +$131K | ﹤0.01% | 1346 |
|
|
2024
Q2 | $209K | Sell |
10,037
-1,941
| -16% | -$40.5K | ﹤0.01% | 1511 |
|
|
2024
Q1 | $176K | Buy |
11,978
+998
| +9% | +$14.7K | ﹤0.01% | 1703 |
|
|
2023
Q4 | $113K | Buy |
+10,980
| New | +$113K | ﹤0.01% | 1760 |
|
|
2022
Q2 | – | Sell |
-10,489
| Closed | -$148K | – | 2009 |
|
|
2022
Q1 | $148K | Sell |
10,489
-2,639
| -20% | -$37.2K | ﹤0.01% | 1956 |
|
|
2021
Q4 | $380K | Sell |
13,128
-377
| -3% | -$10.9K | ﹤0.01% | 1637 |
|
|
2021
Q3 | $405K | Sell |
13,505
-2,589
| -16% | -$77.6K | ﹤0.01% | 1337 |
|
|
2021
Q2 | $427K | Buy |
16,094
+4,265
| +36% | +$113K | ﹤0.01% | 1642 |
|
|
2021
Q1 | $368K | Buy |
11,829
+3,249
| +38% | +$101K | ﹤0.01% | 1671 |
|
|
2020
Q4 | $282K | Buy |
+8,580
| New | +$282K | ﹤0.01% | 1654 |
|